Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (NCT03993873)
A Phase 1/2 of Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of TPX-0022 in Adult Subjects With Locally Advanced or Metastatic NSCLC, Gastric Cancer, or Solid Tumors Harboring Genetic Alterations in MET
🩺 Plain-English Summary (8th-Grade Level)
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)
Who can join: Review the eligibility criteria below.
Location: Local Institution - 2102 — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- Local Institution - 2102 — La Jolla, California
- Local Institution - 2108 — Orange, California
- Local Institution - 2105 — Denver, Colorado
- Local Institution - 2111 — Chicago, Illinois
- Local Institution - 2107 — Boston, Massachusetts
- Local Institution - 2109 — Boston, Massachusetts
- Local Institution - 2106 — Ann Arbor, Michigan
- Local Institution - 2113 — Detroit, Michigan
- Local Institution - 2103 — St Louis, Missouri
- Local Institution - 2104 — Toledo, Ohio
- Local Institution - 2101 — Houston, Texas
- Local Institution - 2112 — Fairfax, Virginia
- Local Institution - 4202 — La Tronche, Auvergne-Rhône-Alpes
- Local Institution - 4203 — Saint-Mandé, Val-de-Marne
- Local Institution - 4204 — Villejuif, Val-de-Marne
- Local Institution - 4201 — Lyon,
- Local Institution - 6304 — Seoul,
- Local Institution - 6301 — Seoul, Seoul-teukbyeolsi [Seoul]
- Local Institution - 6303 — Seoul,
- Local Institution - 6302 — Seoul,
- Local Institution - 4104 — Madrid,
- Local Institution - 4103 — Madrid,
- Local Institution - 4101 — Madrid,
- Local Institution - 4102 — Pamplona,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.